Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up



Status:Recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:May 2014
End Date:December 2018
Contact:Kristen Rushton
Email:krushton@myriad.com

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Referral Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients

This registry is intended to measure the effect of myPlan Lung Cancer™ test has on treatment
decisions of Surgeons when added to standard clinical-pathological parameters in patients
with early stage NSCLC.The sponsor is conducting two parallel registries, with one directed
at Surgeons (ONC003) and the other at Oncologists (ONC006).This registry is specific to
Surgeons (ONC003). Outcomes measures on lung cancer relapse and death from any cause will be
collected.


Inclusion Criteria:

- Diagnosis of early stage non-small cell lung adenocarcinoma

- Sub-population staging (IA, IB or IIA) as judged by the standard of practice at the
investigational site

- Resection of tumor within previous 2 months of enrollment

- ECOG performance of 0-2

- A minimum life expectancy of six months

Exclusion Criteria:

- Pre-operative radiation or chemotherapy for NSCLC

- Post-operative radiation or chemotherapy for NSCLC

- Enrollment in a separate clinical trial restricting treatment options

- Unable to provide informed consent
We found this trial at
1
site
Clinical Trial Facility in Seattle Washington
Seattle, Washington 98105
Principal Investigator: Vallieres
?
mi
from
Seattle, WA
Click here to add this to my saved trials